Skip to content

The effect of BerriQi® Boysenberry and apple product on lung function following ozone exposure

Investigating the effect of BerriQi® Boysenberry and apple product consumption on lung function and immune protection following acute ozone exposure induced lung inflammation in healthy volunteers.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12621000774820
Enrollment
80
Registered
2021-06-21
Start date
2023-01-02
Completion date
2023-06-30
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

There is growing concern about the health impacts of pollution, with increased industrialisation and population growth causing people to work and live in areas with poor air quality.Fruits and vegetables can contain various bioactives that have been reported to impact on airway inflammation, tissue remodelling and immune function. The overall aim of this study is to evaluate the efficacy of a Boysenberry and apple juice beverage consumption in reducing ozone-induced lung inflammation and maintaining normal lung function.

Interventions

BerriQi® Boysenberry and apple powder capsules –1000mg. The capsules are commercially prepared from freeeze dried and milled Boysenberry and apple. The capsules will be formulated to contain a known amount of total anthocyanins so thatparticipants can consume a total of 1400mg total anthocyanins in one or two capsules. The capsules will be consumed daily for 5 days prior to the ozone exposure, on the day of the ozone exposure 1 hour before ozone exposure and then for 2 days following the ozone

BerriQi® Boysenberry and apple powder capsules –1000mg. The capsules are commercially prepared from freeeze dried and milled Boysenberry and apple. The capsules will be formulated to contain a known amount of total anthocyanins so thatparticipants can consume a total of 1400mg total anthocyanins in one or two capsules. The capsules will be consumed daily for 5 days prior to the ozone exposure, on the day of the ozone exposure 1 hour before ozone exposure and then for 2 days following the ozone exposure. To monitor adherence, participants will be given one week's worth of capsules for the first week and asked to return the unconsumed capsules. All participants will undergo a 2 week washout prior to starting the study, the dietary intervention duration is 8 days with ozone or control exposure on day 6 followed by another 2 week washout period and 8 days of the same dietary intervention with ozone or control exposure on day 6 (opposite of what they were previously exposed to) before the participants cross-over onto the other dietary intervention. All participants will be exposed to ozone at a set concentration within a controlled environment for 2 hours to induce acute lung inflammation. the exact concentration will be determined in a pilot study. All participants will also be exposed to plain air within a controlled environment for 2 hours as a control.

Sponsors

The New Zealand Institute for Plant and Food Research
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy male and female (50/50) non-pregnant individuals 18-40 years of age with normal lung function at baseline will be selected

Exclusion criteria

• If they are unwilling or unable to provide informed written consent or comply with the study procedures. • If they have known hypersensitivity or intolerance to Boysenberry or apple-derived products and/or specific food additives. • If they have a diagnosed health conditions that impair their lung function (asthma, COPD, fibrosis), diabetes or cardiovascular disease. • If they smoke. If they have a job where they have high occupational exposure to respiratory irritants such as ozone or particulate matter (eg welder) In addition, participants will also be excluded if they have the following health conditions: (i) blood borne diseases (e.g. hepatitis), (ii) clinically diagnosed high/low blood pressure, (iii) recent bacterial or viral illness or (iv) are taking medication that affects the properties of blood (e.g. blood clotting)

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026